Other substances

ACE2 1–618-ABD

A SARS-CoV-2 Spike protein decoy.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

ACE2 1–618-ABD is a shortened version of the human ACE2 receptor fused with an albumin binding domain. It is used experimentally as a decoy for SARS-CoV-2 Spike protein. It was shown to be stable in plasma and neutralized SARS-CoV-2 infection in human kidney organoids (Wysocki et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids
Enzyme assay In vitro 		in vitro binding assay; in vitro enzyme assay; human kidney organoids; SARS-CoV-2 strain nCoV/Wasington1/2020 9.27

The ACE2-derived fusion protein retained its enzymatic activity and biological activity and bound the SARS-CoV-2 Spike protein RBD in vitro. At 200 µg/ml it protected human kidney organoids from live SARS-CoV-2 virus infection, as assessed by significantly reduced viral replication on day 3 post viral challenge.

 Feb/01/2021
Export (.csv)